Valneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $6.30, but opened at $5.89. Valneva shares last traded at $5.9640, with a volume of 4,518 shares traded.
Analysts Set New Price Targets
VALN has been the subject of several recent analyst reports. Wall Street Zen lowered shares of Valneva to a “strong sell” rating in a report on Saturday, April 25th. Guggenheim set a $11.00 price objective on Valneva in a report on Thursday, April 16th. Finally, The Goldman Sachs Group cut Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective on the stock. in a research note on Wednesday, April 22nd. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Valneva has an average rating of “Hold” and an average target price of $11.98.
Get Our Latest Research Report on VALN
Valneva Price Performance
Valneva (NASDAQ:VALN – Get Free Report) last issued its earnings results on Sunday, February 15th. The company reported ($0.68) EPS for the quarter. Valneva had a negative net margin of 67.64% and a negative return on equity of 76.81%. The company had revenue of $55.92 million during the quarter. Equities research analysts expect that Valneva SE Sponsored ADR will post -0.81 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Marex Group plc bought a new stake in shares of Valneva during the second quarter valued at approximately $64,000. XTX Topco Ltd bought a new position in Valneva in the 4th quarter worth approximately $94,000. JPMorgan Chase & Co. acquired a new stake in Valneva in the 3rd quarter valued at approximately $124,000. China Universal Asset Management Co. Ltd. acquired a new stake in Valneva in the 4th quarter valued at approximately $44,000. Finally, VSM Wealth Advisory LLC raised its stake in Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after acquiring an additional 5,000 shares in the last quarter. 11.39% of the stock is owned by institutional investors and hedge funds.
Valneva Company Profile
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.
Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.
Featured Articles
- Five stocks we like better than Valneva
- Shake Shack Stock Gets Shaken After Earnings Miss
- On Holdings Sets Up for Marathon Rally: New Highs Are Coming
- The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000
- MP Materials Is Quietly Building a Rare Earth Powerhouse
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
